Evidence map›Paper›PMID 42300994›Full record

ArticleIranian biomedical journal2026

Antiviral Potential of Lipopeptide Biosurfactant Isolated from Acinetobacter junii B6.

Amir Mohammad Bagheri, Hamid Forootanfar, Gholamreza Dehghannoudeh, Mohammad Amin Raeisi Estabragh, Ibrahim M. Banat, Hosnieh Sokhandan, Hadiseh Shokouhi, Mandana Ohadi, Parvaneh Mehrbod

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian biomedical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amir Mohammad BagheriHerbal and Traditional Medicines Research Center, Institute of Pharmaceutical Sciences, Kerman University of Medical Sciences, Kerman, Iran.
Hamid ForootanfarPharmaceutical Sciences and Cosmetic Products Research Center, Institute of Pharmaceutical Sciences, Kerman University of Medical Sciences, Kerman, Iran.
Gholamreza DehghannoudehDepartment of Pharmaceutics, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.
Mohammad Amin Raeisi EstabraghDepartment of Pharmaceutics, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.
Ibrahim M. BanatSchool of Biomedical Sciences, Faculty of Life & Health Sciences, Ulster University, Coleraine BT52 1SA, N. Ireland, UK.
Hosnieh SokhandanInfluenza and Respiratory Viruses Department, Pasteur Institute of Iran, Tehran, Iran.
Hadiseh ShokouhiInfluenza and Respiratory Viruses Department, Pasteur Institute of Iran, Tehran, Iran.
Mandana OhadiPharmaceutics Research Center, Institute of Pharmaceutical Sciences, Kerman University of Medical Sciences, Kerman, Iran.
Parvaneh MehrbodInfluenza and Respiratory Viruses Department, Pasteur Institute of Iran, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Influenza A virus (IAV) is a global health concern, increasing the exploration of alternative therapeutics. Biosurfactants (BSs) are biodegradable, non-toxic biomolecules with favorable biological activities. Acinetobacter junii B6, known for utilizing crude oil as a carbon and energy source, produces BSs. This study evaluated the antiviral potential of the lipopeptide biosurfactant (LPB) against H1N1/A/PR8/34 infection. Methods: A. junii B6 LPB was extracted and characterized in our previous study. The 50% cytotoxic concentration and non-cytotoxic concentration (NCTC), defined as the concentration with no toxicity on cells, were determined by the MTT assay on MDCK cells. The NCTC was exposed to the cells in the presence of PR8 (100 TCID50) under simultaneous, pre- and post-exposure combination treatments for 1 h. After 48 h of incubation, the hemagglutination and MTT assays assessed viral propagation and cell protection, respectively. Amantadine and oseltamivir served as antiviral control drugs. Results: The extracted LPB caused a 1 log2 reduction in pre- and post-exposure treatments, whereas amantadine and oseltamivir reduced viral titers by more than 1 log2. Cell protection was favorable in all combination treatments except for LPB co-treatment. LPB extract showed limited but notable anti-IAV activity, alongside cell protection. Conclusion: While LPB is less potent than amantadine and oseltamivir, its non-toxic and environmentally friendly nature warrants further study. As surfactants act on the lipid envelope, viral proteins, and nucleocapsid proteins, LPB could be potentially used as an adjuvant with other antiviral agents to control the prevalence of viral diseases and improve therapeutic outcomes.

Indexed as

AcinetobacterAntiviral AgentsBiosurfactantsInfluenza A Virus, H1N1 SubtypeLipopeptidesAmantadineAnimalsDogsMadin Darby Canine Kidney CellsOseltamivirAmantadineAntiviral AgentsLipopeptidesOseltamivirAcinetobacter juniiAntiviral agentsInfluenza A virusLipopeptides

Identifiers

PMID42300994
PMCPMC13539240

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.